Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
Returns on capital
Seaport Therapeutics, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daphne Zohar | Founder, CEO, President & Director | USD 1.26M | 55 | 1.09M | 2.04% |
Antony Loebel | Chief Medical Officer & President of Clinical Development | USD 670.25K | 65 | — | — |
Michael C. Chen | Co-Founder & Chief Scientific Officer | USD 604.5K | 42 | — | — |
Steven Paul | Founder & Non-Employee Chair of the Board | USD 500K | 75 | — | — |
Lana Gladstein | General Counsel | — | 50 | — | — |
Lauren A. White | Chief Financial Officer | — | 47 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$335,093.00
Sells
0
$0.00
Net Transaction Value
+$335,093.00
Net buying
Most Active
Torres Denice
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 3, 26Nov 3, 2026 | Torres Denice Direct | Buy | $99.3K$99,325.00 |
| Jun 22, 26Jun 22, 2026 | HOMBACH ROBERT J. Indirect | Buy | $235.8K$235,768.00 |
Summary
Insiders reported 2 buys worth $335,093.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $335,093.00. Torres Denice was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Who does Seaport Therapeutics, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SPTX's management, answered from reported figures.
Who manages SPTX?
Seaport Therapeutics, Inc. Common Stock (SPTX) lists 6 active executives. The top listed executive is Antony Loebel, Chief Medical Officer & President of Clinical Development.
Are SPTX insiders buying or selling?
Recent insider activity shows net buying of $335,093.00.
Continue the stock analysis
Jump to another research area for this company.